By Colin Kellaher

 

Merck & Co. on Monday said the U.S. Food and Drug Administration accepted for review its new-drug application for gefapixant for the treatment of refractory chronic cough or unexplained chronic cough in adults.

The Kenilworth, N.J., drugmaker said the FDA set a target action date of Dec. 21 for the review, adding that the agency plans to discuss the application at an advisory committee meeting, which has yet to be scheduled.

Merck said there are currently no approved therapies for the treatment of refractory or unexplained chronic cough.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

March 01, 2021 07:33 ET (12:33 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Merck Charts.